Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Increases Theravance Stake …
by Lisa M. Jarvis
December 6, 2010
| A version of this story appeared in
Volume 88, Issue 49
GlaxoSmithKline is upping its stake in long-standing respiratory drug development partner Theravance. The purchase of 5.7 million shares, worth roughly $130 million, will bring GSK’s total stake in Theravance to about 19%. The relationship between GSK and the South San Francisco-based biotech firm traces back to 2002, when they agreed to develop two treatments incorporating a long-acting β2 agonist (LABA) developed by Theravance. The pact has expanded over the years, and the companies now have three drug candidates in mid- to late-stage clinical trials.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter